Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group

Research output: Contribution to journal › Article › peer-review

132 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences